Physician profile
Brett J Widick
NPI 1477576478
$16,437.42
in general payments reported to CMS, 2019-2025
47 companies · $2,574 in 2025
The $2,574 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,022 · 2020: $1,772 · 2021: $2,411 · 2022: $2,365 · 2023: $2,720 · 2024: $2,573 · 2025: $2,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,867.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,888.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,658.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,461.76 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,350.08 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,228.48 | 2019-2025 | |
| Amgen INC. | $1,016.39 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $778.78 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $600.53 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $473.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $459.49 | 2019-2024 | Gardasil 9, Verquvo, Gardasil |
| Esperion Therapeutics, INC. | $454.19 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $451.85 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $363.28 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $342.90 | 2019-2024 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $326.56 | 2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $269.25 | 2021-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $250.16 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $193.94 | 2020-2021 | |
| Amarin Pharma, INC. | $193.48 | 2019-2022 | |
| Eisai INC. | $193.44 | 2021-2025 | |
| Exact Sciences Corporation | $167.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $152.71 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $143.46 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $106.38 | 2019-2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $95.71 | 2023-2025 | Rexulti |
| Boston Scientific Corporation | $81.67 | 2020-2024 | Watchman Flx, Watchman Access System |
| Abbott Laboratories | $74.26 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Astellas Pharma US INC | $70.18 | 2019-2024 | Veozah |
| Radius Health, INC. | $64.82 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $60.92 | 2020-2025 | Contrave |
| Vivus LLC | $60.24 | 2020-2022 | |
| Tolmar, INC. | $52.69 | 2023-2024 | |
| Axsome Therapeutics, INC. | $45.13 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $43.32 | 2023 | Quviviq |
| Lifescan, INC. | $39.89 | 2022-2023 | |
| Nevro Corp. | $39.31 | 2022-2023 | Senza |
| Dynavax Technologies Corporation | $22.12 | 2023 | Heplisav-B |
| Ibsa Pharma INC. | $19.79 | 2024 | Licart, Tirosint |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.79 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $18.51 | 2022 | |
| Smith+Nephew, INC. | $16.49 | 2023 | Collagenase Santyl, Regranex |
| Gilead Sciences, INC. | $15.89 | 2021 | |
| Almatica Pharma LLC | $15.58 | 2024 | Loreev Xr |
| Lundbeck LLC | $14.77 | 2023 | Rexulti |
| Axonics, INC. | $14.03 | 2021 | |
| Circassia INC. | $13.71 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Widick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.